Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Buhl R, Banerji D. Int J Chron Obstruct Pulmon Dis. 2012; 7:729-741. On page 737 in the first paragraph of the "Safety" section, the final sentence "Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (11%) compared with placebo (13%) and the tiotropium group (15% , Table 3) . 32, 33 " should read "Serious adverse events occurred with a slightly lower frequency in the glycopyrronium treatment group (10%) compared with placebo (13%) and the tiotropium group (15% , Table 3 ). 32, 33 " On page 737 in the second paragraph of the "Safety" section, the first sentence "Discontinuations due to adverse events were 10% in the placebo group and 8% in the glycopyrronium and tiotropium groups." should read "Discontinuations due to adverse events were 9% in the placebo group and 7% in the glycopyrronium and tiotropium groups."
On page 737, Table 3 contains incorrect information. The corrected Table is set out below. 
